Exosome Diagnostics, Inc. news
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro diagnostic (IV
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA assay. ExoTRU was developed in collaboration with the Azzi laboratory at the Transplantation Research Center at Brigham and Women’s Hospital, Harvard Medical School. The ExoTRU test will be the first ever commercially a
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-ba
Dr. James McKiernan, Professor of Urology at Columbia University, demonstrated that using the ExoDx Prostate test, or EPI, resulted in good performance ruling out high-grade (Gleason 7 or higher) prostate cancer (HGPCa) in prior negative biopsy patients with the previously validated 15.6 cut-point.
Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Can
Bio-Techne Corporation (NASDAQ:TECH)
today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with Hall of Famer and baseball`s all-time "Iron Man", Cal Ripken Jr. This year marks 25 years since Ripken played in his 2,131st consecutive game, eclipsing the thought to be unbreakable record of 2,130 set by the legendary Lou Gehrig. Recently the 21-year Major League veteran divulged that earlier this year he was diagnosed with and succe